We found that 10 of 42 (24%) tumours contained at least one somatic mutation in a candidate or high-confidence tumour driver gene34, although there was no enrichment in tumours lacking somatic TSC1/TSC2 inactivation (that is, tumours with less than two TSC1/TSC2 mutations) (Supplementary Data 3). The gene discussed is TSC2; the disease is neoplasm.